Biochemist Richard DiMarchi is ‘true entrepreneur’
Biochemist has founded or co-founded five startups since retiring from Eli Lilly and Co. as head of biotechnology research 13 years ago, at age 50.
Richard DiMarchi
Articles
Novo Nordisk buying 2 DiMarchi-launched drug firms
Calibrium LLC and MB2 LLC, both based in Carmel, have agreed to be sold for undisclosed amounts. They were developing diabetes drugs discovered by the research team of Richard DiMarchi, a chemistry professor at Indiana University.
IU prof DiMarchi to join Inventors Hall of Fame
Richard DiMarchi is being honored for his work on Eli Lilly and Co.'s Humalog, which has been used by millions around the world to address the complications of diabetes.
Ex-Marcadia execs raise $1.7M to launch drug firm
Fritz French and Richard DiMarchi, the former leaders of Marcadia Biotech, have teamed up to launch the diabetes drug development firm Calibrium LLC.
IU chemist DiMarchi receives science award from Daniels
Richard DiMarchi helped develop the sepsis-treating drug Xigris for Eli Lilly and Co. He also co-founded Marcadia Biotech, which Roche acquired in 2010 for an initial upfront payment of $287 million.
Indiana life sciences leaders look toward the future
Former Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry in Indiana to venture capital and Purdue’s Discovery Park.
21st Century Fund pockets a payoff from sale
The state’s principal fund investing in high-tech companies has reached a milestone—for the first time recouping all the money it granted an emerging company, and then some.
Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Marcadia enlists Lilly to help develop new diabetes drug
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
Ex-Lilly execs take on diabetes with Carmel startup
Four former top scientists at Eli Lilly and Co. have formed a Carmel-based company to develop diabetes therapies–a venture observers say has the potential to become the kind of blockbuster success BioCrossroads was built to stimulate.